Compare · CLPT vs MDLN
CLPT vs MDLN
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.60B, about 89.1x CLPT ($511.6M).
- Over the past year, CLPT is up 49.9% and MDLN is down 14.9% - CLPT leads by 64.8 points.
- MDLN has been more active in the news (18 items in the past 4 weeks vs 4 for CLPT).
- MDLN has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- ClearPoint Neuro Inc.
- Medline Inc.
- Price
- $17.06-4.26%
- $34.68-3.43%
- Market cap
- $511.6M
- $45.60B
- 1M return
- +52.59%
- -4.30%
- 1Y return
- +49.91%
- -14.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 18
- Recent ratings
- 5
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
Latest CLPT
- CEO and President Burnett Joseph exercised 60,000 shares at a strike of $2.50 and sold $1,100,463 worth of shares (61,843 units at $17.79) as part of a pre-agreed trading plan (SEC Form 4)
- Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers
- Director Richards Timothy T. exercised 500 shares at a strike of $10.00 and covered exercise/tax liability with 376 shares, increasing direct ownership by 0.14% to 87,322 units (SEC Form 4)
- Director Richards Timothy T. sold $65,901 worth of shares (5,415 units at $12.17), decreasing direct ownership by 6% to 87,198 units (SEC Form 4)
- ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form 4 filed by Director Johnson B Kristine
- SEC Form 4 filed by Director Liau Linda M.
- SEC Form 4 filed by Director Fallon Lynnette C
- SEC Form 4 filed by Director Fletcher R John
- Director Klein Matthew B. sold $185,440 worth of shares (16,000 units at $11.59), decreasing direct ownership by 25% to 46,935 units (SEC Form 4)
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)